Lacutamab

Lacutamab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 021-61312847; 18021002903
Email: 3008007409@qq.com
Products Intro: Product Name:Lacutamab (anti-KIR3DL2)
CAS:2187368-16-5
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:100μg Remarks:K13809
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Lacutamab
CAS:2187368-16-5
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Lacutamab
CAS:2187368-16-5
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Lacutamab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Email: marketing@tsbiochem.com
Products Intro: Product Name:Lacutamab
CAS:2187368-16-5
Package:1removed
Lacutamab Basic information
Product Name:Lacutamab
Synonyms:Lacutamab;Research Grade Lacutamab (DHE43801);IPH 41|||IPH 4102;Research Grade Lacutamab;Lacutamab (anti-KIR3DL2)
CAS:2187368-16-5
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Lacutamab Structure
Lacutamab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Lacutamab Usage And Synthesis
UsesLacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma[1].
References[1] Van Der Weyden C, et, al. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018 Aug;27(8):691-697. DOI:10.1080/13543784.2018.1498081
Lacutamab Preparation Products And Raw materials
Tag:Lacutamab(2187368-16-5) Related Product Information
Bedinvetmab Firivumab Dectrekumab Crenezumab Romilkimab Duligotuzumab Anselamimab Ginisortamab Vepsitamab Nofazinlimab